$2.76 Billion is the total value of Tekla Capital Management LLC's 212 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BHC | New | Bausch Health Companies Inc. | $4,929,000 | – | 192,000 | +100.0% | 0.18% | – |
| ANAB | New | AnaptysBio, Inc. | $4,580,000 | – | 45,910 | +100.0% | 0.17% | – |
| ALGN | New | Align Technology, Inc. | $4,399,000 | – | 11,244 | +100.0% | 0.16% | – |
| DGX | New | Quest Diagnostics Incorporated | $4,208,000 | – | 39,000 | +100.0% | 0.15% | – |
| A | New | Agilent Technologies, Inc. | $4,007,000 | – | 56,800 | +100.0% | 0.14% | – |
| STRO | New | Sutro Biopharma, Inc. | $3,750,000 | – | 250,000 | +100.0% | 0.14% | – |
| MRNS | New | Marinus Pharmaceuticals, Inc. | $3,362,000 | – | 336,228 | +100.0% | 0.12% | – |
| NITE | New | Nightstar Therapeutics plcadr | $3,065,000 | – | 150,000 | +100.0% | 0.11% | – |
| MYOK | New | MyoKardia, Inc. | $2,517,000 | – | 38,600 | +100.0% | 0.09% | – |
| LGND | New | Ligand Pharmaceuticals Incorporated | $2,454,000 | – | 8,940 | +100.0% | 0.09% | – |
| GHDX | New | Genomic Health, Inc. | $2,439,000 | – | 34,740 | +100.0% | 0.09% | – |
| AERI | New | Aerie Pharmaceuticals, Inc. | $2,386,000 | – | 38,770 | +100.0% | 0.09% | – |
| PTCT | New | PTC Therapeutics, Inc. | $2,274,000 | – | 48,390 | +100.0% | 0.08% | – |
| XRAY | New | DENTSPLY SIRONA Inc. | $2,174,000 | – | 57,600 | +100.0% | 0.08% | – |
| IQV | New | IQVIA Holdings Inc. | $2,180,000 | – | 16,800 | +100.0% | 0.08% | – |
| RGEN | New | Repligen Corporation | $2,146,000 | – | 38,700 | +100.0% | 0.08% | – |
| MTD | New | Mettler-Toledo International Inc. | $2,131,000 | – | 3,500 | +100.0% | 0.08% | – |
| LH | New | Laboratory Corporation of America Holdingssponsored adr | $2,119,000 | – | 12,200 | +100.0% | 0.08% | – |
| WAT | New | Waters Corporation | $2,103,000 | – | 10,800 | +100.0% | 0.08% | – |
| IMMU | New | Immunomedics, Inc. | $2,028,000 | – | 97,370 | +100.0% | 0.07% | – |
| SPPI | New | Spectrum Pharmaceuticals, Inc. | $1,926,000 | – | 114,670 | +100.0% | 0.07% | – |
| INOV | New | Inovalon Holdings, Inc. | $1,770,000 | – | 176,163 | +100.0% | 0.06% | – |
| ABMD | New | ABIOMED, Inc. | $1,687,000 | – | 3,750 | +100.0% | 0.06% | – |
| IMGN | New | ImmunoGen, Inc. | $1,593,000 | – | 168,190 | +100.0% | 0.06% | – |
| BOLD | New | Audentes Therapeutics, Inc. | $1,534,000 | – | 38,740 | +100.0% | 0.06% | – |
| PHG | New | Koninklijke Philips N.V.ny reg sh | $1,506,000 | – | 33,100 | +100.0% | 0.06% | – |
| MDGL | New | Madrigal Pharmaceuticals, Inc. | $1,428,000 | – | 6,670 | +100.0% | 0.05% | – |
| ARQL | New | ArQule, Inc. | $1,415,000 | – | 250,000 | +100.0% | 0.05% | – |
| CNCE | New | Concert Pharmaceuticals, Inc. | $1,346,000 | – | 90,724 | +100.0% | 0.05% | – |
| ECYT | New | Endocyte, Inc. | $746,000 | – | 41,980 | +100.0% | 0.03% | – |
| LXRX | New | Lexicon Pharmaceuticals, Inc.sponsored adr | $747,000 | – | 70,000 | +100.0% | 0.03% | – |
| ITCI | New | Intra-Cellular Therapies, Inc. | $756,000 | – | 34,850 | +100.0% | 0.03% | – |
| RYTM | New | Rhythm Pharmaceuticals, Inc.sponsored adr | $726,000 | – | 24,890 | +100.0% | 0.03% | – |
| ATNX | New | Athenex, Inc. | $708,000 | – | 45,530 | +100.0% | 0.03% | – |
| MRTX | New | Mirati Therapeutics, Inc. | $640,000 | – | 13,590 | +100.0% | 0.02% | – |
| EIDX | New | Eidos Therapeutics, Inc. | $278,000 | – | 27,900 | +100.0% | 0.01% | – |
| MNLO | New | Menlo Therapeutics Inc. | $244,000 | – | 24,784 | +100.0% | 0.01% | – |
| XENT | New | Intersect ENT, Inc. | $240,000 | – | 8,356 | +100.0% | 0.01% | – |
| ASRT | New | Assertio Therapeutics, Inc. | $6,000 | – | 1,000 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.